Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.37 |
| ▸ | CACNA1B known ✓ | Q00975 | 2/20 | 0.36 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 8/20 | 0.35 |
| ▸ | NPY1R | P25929 | 5/20 | 0.35 |
| ▸ | NPY2R | P49146 | 3/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.35 |
| ▸ | OTC | P00480 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7367067 | 1.00 | FOLH1 (0.37) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| Hydrochloric Acid SCHEMBL1578565 | 1.00 | FOLH1 (0.37) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| SCHEMBL17769024 | 0.98 | FOLH1 (0.38) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| SCHEMBL93472 | 0.98 | FOLH1 (0.38) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| SCHEMBL93473 | 0.98 | FOLH1 (0.38) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| SCHEMBL162756 | 0.98 | FOLH1 (0.38) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| Acetic Acid SCHEMBL160844 | 0.95 | FOLH1 (0.39) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| Acetic Acid SCHEMBL2170653 | 0.95 | FOLH1 (0.39) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| Acetic Acid SCHEMBL1551710 | 0.95 | FOLH1 (0.39) | FOLH1ITGB3ITGA2BCACNA1BC3AR1 | |
| SCHEMBL8663352 | 0.93 | FOLH1 (0.43) | FOLH1ALOX15MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882014-A1 | PROCESS FOR THE PREPARATION OF N?G -MONOMETHYL-L-ARGININE HYDROCHLORIDE | GLAXO GROUP LIMITED (GB) | 1998-12-09 | — | — | EP | claimed |
| WO-1997030972-A1 | PROCESS FOR THE PREPARATION OF NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE | GLAXO GROUP LIMITED (GB) | 1997-08-28 | — | — | WO | claimed |
| EP-0651741-B1 | NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | WELLCOME FOUND (GB) | 1997-01-29 | — | — | EP | claimed |
| EP-0651741-A1 | N?G -MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK. | WELLCOME FOUND (GB) | 1995-05-10 | — | — | EP | claimed |
| CN-1087624-A | Arginine derivative | WELLCOME FOUND (GB) | 1994-06-08 | — | — | CN | claimed |
| WO-1994002453-A1 | NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-03 | — | — | WO | claimed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| US-10385009-B2 | Deuterated compounds and uses thereof | BIOSTATUS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| EP-2564871-B1 | Therapeutic Agent for Migraine | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-9254283-B2 | Therapeutic agent for migraine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20150307441-A1 | NEW COMPOUNDS AND USES THEREOF | BIOSTATUS LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| CN-104837814-A | Novel compound and use thereof | BIOSTATUS LTD | 2015-08-12 | — | — | CN | disclosed |
| EP-2882708-A1 | NEW COMPOUNDS AND USES THEREOF | Biostatus Limited (GB) | 2015-06-17 | — | — | EP | disclosed |
| EP-0696274-A1 | PROCESS FOR PREPARING NG-MONOALKYL-L-ARGININE AND RELATED COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-14 | — | — | EP | disclosed |
| EP-0651741-A1 | N?G -MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK. | WELLCOME FOUND (GB) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994026701-A1 | PROCESS FOR PREPARING NG-MONOALKYL-L-ARGININE AND RELATED COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| EP-0610432-A1 | C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-17 | — | — | EP | disclosed |
| CN-1087624-A | Arginine derivative | WELLCOME FOUND (GB) | 1994-06-08 | — | — | CN | disclosed |
| WO-1994002453-A1 | NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993009133-A1 | C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385009-B2 | Deuterated compounds and uses thereof | HIF1AN, HIF1A, EGLN2 | ITGB3 3454/4885ITGA2B 2768/4885CACNA1B 4729/4885 |
| US-20150307441-A1 | NEW COMPOUNDS AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | ITGB3 3091/4885ITGA2B 1592/4885CACNA1B 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.